Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Day One Biopharmaceuticals (DAWN – Research Report) and keeping the price target at $36.00.
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the promising trajectory of Day One Biopharmaceuticals. The company has shown consistent growth with its product OJEMDA, achieving significant sequential revenue increases and a notable rise in cumulative prescriptions. This growth is supported by strategic efforts to deepen prescribing within key accounts and expand through educational initiatives, ensuring a high rate of on-label use and sustained patient adherence.
Furthermore, Day One Biopharmaceuticals is advancing its pipeline with the FIREFLY-2 trial, which could further solidify OJEMDA’s position in the market. The company’s focus on overcoming physician conservatism in pediatric oncology, coupled with the promising early-stage development of its anti-PTK7 ADC, underscores a robust strategy for long-term success. These elements collectively reinforce Maldonado’s confidence in the company’s potential, justifying the Buy rating.
In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $20.00 price target.